Hudson Edge Investment Partners’s Royalty Pharma RPRX Stock Holding History

Hudson Edge Investment Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,482	Closed	-$486K	–	134
2023 Q1	$486K	Buy	13,482 +1,757	+15%	+$65.1K	0.15%	104
2022 Q4	$463K	Hold	11,725	–	–	0.16%	114
2022 Q3	$471K	Hold	11,725	–	–	0.18%	105
2022 Q2	$493K	Hold	11,725	–	–	0.18%	111
2022 Q1	$457K	Buy	11,725 +580	+5%	+$22.8K	0.14%	124
2021 Q4	$444K	Buy	+11,145	New	+$433K	0.14%	126

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Edge Investment Partners's RPRX Position: Q2 2023 in Review

Hudson Edge Investment Partners sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 13,482 shares — an estimated $486K sold.

Hudson Edge Investment Partners first reported a position in RPRX in Q4 2021 and held it in 6 quarters. The position peaked at $493K in Q2 2022. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Hudson Edge Investment Partners reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Hudson Edge Investment Partners sold 13,482 Royalty Pharma shares in Q2 2023, an estimated $486K.
Hudson Edge Investment Partners first reported a position in Royalty Pharma in Q4 2021 and held it in 6 quarters.
Hudson Edge Investment Partners's Royalty Pharma position peaked at $493K in Q2 2022.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Hudson Edge Investment Partners's 13F filing for Q2 2023, filed 2 Aug 2023.